Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant

This randomized clinical trial examines the efficacy of ivonescimab plus chemotherapy vs chemotherapy alone for patients with advanced or metastatic non–small cell lung cancer with the epidermal growth factor receptor (EGFR) variant.